Belay Elshaday S, Flamant Etienne, Sugarman Barrie, Goltz Daniel E, Klifto Christopher S, Anakwenze Oke
Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA.
Duke University School of Medicine, Durham, NC, USA.
JSES Int. 2020 Sep 8;5(1):149-153. doi: 10.1016/j.jseint.2020.07.020. eCollection 2021 Jan.
Identifying areas of excess cost for shoulder arthroplasty patients can play a role in effective health care spending. The purpose of this study was to assess the utility of postoperative complete blood count (CBC) testing after total shoulder arthroplasty (TSA) and identify which patients benefit from routine CBC testing.
We performed a retrospective review of a cohort of patients who underwent primary TSA from January 2018 through January 2019. All patients in this cohort received tranexamic acid. Patient demographic characteristics and patient-specific risk factors such as American Society of Anesthesiologists score, Elixhauser index, body mass index, smoking status, and coagulopathy history were obtained. Perioperative values including length of surgery, preoperative and postoperative hemoglobin (Hgb) levels, and need for transfusion were also obtained.
This study included 387 TSA patients in the final analysis. Comparison between the cohort requiring transfusion and the cohort undergoing no intervention revealed no statistically significant differences in age, sex, body mass index, American Society of Anesthesiologists score, or Elixhauser index. The group receiving transfusions was found to have significantly lower levels of preoperative Hgb (11.3 g/dL) and postoperative Hgb (8.1 g/dL) ( < .0001). Additionally, the percentages of patients with abnormal preoperative Hgb levels (<12 g/dL) (72.3%) and postoperative day 1 Hgb levels < 9 g/dL (81.8%) were significantly higher in the group receiving transfusions ( < .0001). A multivariate regression model identified an abnormal preoperative Hgb level (<12 g/dL), with an odds ratio of 3.8 (95% confidence interval, 1.5-6.2; < .001), and postoperative day 1 Hgb level < 9 g/dL, with an odds ratio of 3.3 (95% confidence interval, 0.4-6.1; < .03), as significant predictors of the risk of transfusion with a sensitivity of 64% and specificity of 96.2% with an area under the curve of 0.87.
Routine CBC testing may not be necessary for patients who receive tranexamic acid and have preoperative Hgb levels > 12 mg/dL and first postoperative Hgb levels > 9 mg/dL. This translates to potential health care cost savings and improves current evidence-based perioperative management in shoulder arthroplasty.
识别肩关节置换患者的额外高成本领域对有效医疗支出具有重要意义。本研究旨在评估全肩关节置换术(TSA)后术后全血细胞计数(CBC)检测的效用,并确定哪些患者能从常规CBC检测中获益。
我们对2018年1月至2019年1月接受初次TSA的一组患者进行了回顾性研究。该队列中的所有患者均接受了氨甲环酸治疗。获取了患者的人口统计学特征以及患者特定的风险因素,如美国麻醉医师协会评分、埃利克斯豪泽指数、体重指数、吸烟状况和凝血病史。还获取了围手术期数据,包括手术时长、术前和术后血红蛋白(Hgb)水平以及输血需求。
最终分析纳入了387例TSA患者。需要输血的队列与未接受干预的队列在年龄、性别、体重指数、美国麻醉医师协会评分或埃利克斯豪泽指数方面无统计学显著差异。发现接受输血的组术前Hgb水平(11.3 g/dL)和术后Hgb水平(8.1 g/dL)显著更低(<.0001)。此外,接受输血的组术前Hgb水平异常(<12 g/dL)的患者百分比(72.3%)和术后第1天Hgb水平<9 g/dL的患者百分比(81.8%)显著更高(<.0001)。多因素回归模型确定术前Hgb水平异常(<12 g/dL),比值比为3.8(95%置信区间,1.5 - 6.2;<.001),以及术后第1天Hgb水平<9 g/dL,比值比为3.3(95%置信区间,0.4 - 6.1;<.03),是输血风险的显著预测因素,其敏感性为64%,特异性为96.2%,曲线下面积为0.87。
对于接受氨甲环酸治疗且术前Hgb水平 > 12 mg/dL和术后首次Hgb水平 > 9 mg/dL的患者,可能无需进行常规CBC检测。这意味着潜在的医疗成本节约,并改善了当前肩关节置换术中基于证据的围手术期管理。